| Title: | A Distinct Immunological Signature in Late-Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study |
| Journal: | Annals of Neurology |
| Published: | 6 Sep 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40913424/ |
| DOI: | https://doi.org/10.1002/ana.78017 |
Publication 19554
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
OBJECTIVE: Approximately 80% of patients with myasthenia gravis (MG) have autoantibodies against acetylcholine receptor, and clinical characteristics may vary between early-onset (symptom onset age <50 years) and late-onset MG (EOMG and LOMG), but the pathophysiological differences between EOMG and LOMG are not well established.</p>
METHODS: We performed an exploratory in-depth proteomics analysis examining 768 inflammatory proteins utilizing the baseline serum samples from the BeatMG study (NCT02110706). We performed pathway enrichment analysis to assess the pathways involved in LOMG. A total of 15 selected proteins from the initial analysis were further examined using the UK Biobank and further quantified in a separate validation cohort.</p>
RESULTS: A total of 21 patients with EOMG (age 38.3 ± 12.1 years, 16 women [76.2%]) and 28 patients with LOMG (age 67.3 ± 8.6 years, 7 women [25%]) from the BeatMG study were included in the exploratory analysis. Several proteins involved in the regulation of leukocyte differentiation and myeloid leukocyte differentiation and migration pathways were more abundant in the LOMG group. Among them, 7 were significantly different in the UK Biobank cohort. A total of 80 participants (39 MG patients (age 54.33 ± 18.9 years, 17 women [43.6%]) and 41 healthy controls (age 49.56 ± 17.06 years, 21 women [66.1%]) were included in the validation cohort, and IL18R1, CXCL17, and CCL11 were validated to be specific for LOMG.</p>
INTERPRETATION: Growing evidence supports that LOMG has a distinct immune pathomechanism. Further prospective studies are warranted to confirm the utility of these proteins as biomarkers of LOMG, and the feasibility of using them for more precise therapeutic targets to improve patient outcomes. ANN NEUROL 2026;99:198-210.</p>
12 Keywords
- Adult
- Age of Onset
- Aged
- Autoantibodies
- Biomarkers
- Cohort Studies
- Female
- Humans
- Male
- Middle Aged
- Myasthenia Gravis
- Proteomics
10 Authors
- Bhaskar Roy
- Jiaxin Chen
- Fatemeh Khani-Habibabadi
- Nilay McLaren
- Betty C. Soliven
- Vern C. Juel
- Kevin C. O'Connor
- Richard J. Nowak
- Linda L. Kusner
- Henry J. Kaminski
1 Application
| Application ID | Title |
|---|---|
| 189667 | Biomarkers for late-onset myasthenia gravis |
Enabling scientific discoveries that improve human health